As drug prices continue to rise, the 340B drug pricing program continues to help hospitals expand access to comprehensive health services, including lifesaving prescription drugs for those in need who may not be able to afford them, writes AHA President and CEO Rick Pollack in the Wall Street Journal.    
    
“It is in the best interest of all to keep the 340B program strong so that our nation’s patients and communities can continue to receive the high-quality care and services on which they depend,” the advertorial adds.  

Related News Articles

Headline
Following the recent district court decision to remand to the Department of Health and Human Services the question of how to repay 340B hospitals for…
Headline
Drugmakers that participate in the 340B drug pricing program do not have to provide discounted 340B drugs to an unlimited number of contract pharmacies, the U.…
Headline
The U.S. District Court for the District of Columbia today decided to allow the Department of Health and Human Services to propose an appropriate remedy for…
Perspective
The convening of the 118th Congress this week is a reminder of Washington’s highly-charged political environment. The once-in-a-century floor tussle over the…
Headline
The Department of Health and Human Services today issued a new proposed rule revising the 2020 final rule that established the 340B Administrative Dispute…
Headline
The AHA today released a new report showing how the unlawful actions of drug companies to limit 340B pricing with community and specialty pharmacies are…